Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy

Nature Neuroscience

Volumn 10, Issue 11, 2007, Pages 1407-1413

  Vilchez, David ^a   Ros, Susana ^a   Cifuentes, Daniel ^a   Pujadas, Lluís ^a   Vallès, Jordi ^a   García Fojeda, Belén ^b   Criado García, Olga ^b   Fernández Sánchez, Elena ^b   Medrão Fernández, Iria ^b   Domínguez, Jorge ^a   García Rocha, Mar ^a   Soriano, Eduardo ^a   Rodríguez De Córdoba, Santiago ^b   Guinovart, Joan J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; GLYCOGEN; GLYCOGEN SYNTHASE; LAFORIN; MALIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEASOME; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRAIN HEK293; COMPLEX FORMATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EMBRYO; ENZYME ACTIVITY; GENE MUTATION; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; MYOCLONUS EPILEPSY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; APOPTOSIS; ASTROCYTES; CARRIER PROTEINS; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; HUMANS; IN SITU NICK-END LABELING; MICE; MUTATION; NEURONS; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; RNA INTERFERENCE; TRANSFECTION; TUBULIN;

EID: 35548995067     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn1998     Document Type: Article

References (46)

1. Brown, A.M. Brain glycogen re-awakened. J. Neurochem. 89, 537-552 (2004).
2. Cavanagh, J.B. Corpora-amylacea and the family of polyglucosan diseases. Brain Res. Brain Res. Rev. 29, 265-295 (1999).
3. Berkovic, S.F., Andermann, F., Carpenter, S. & Wolfe, L.S. Progressive myoclonus epilepsies: specific causes and diagnosis. N. Engl. J. Med. 315, 296-305 (1986).
4. Lafora, G.R. Über das corkommen amyloider körperchen im innern der ganglienzellen; zugliech ein zum studium der amyloiden substanz im nervensystem. Virchows Arch. Pathol. Anat. 205, 294-303 (1911).
5. Lafora, G.R. & Glueck, B. Beitrag zur histogpathologie der myoklonischen epilepsie. Z. Gesamte Neurol. Psychiatr. 6, 1-14 (1911).
6. Collins, G.H., Cowden, R.R. & Nevis, A.H. Myoclonus epilepsy with Lafora bodies. An ultrastructural and cytochemical study. Arch. Pathol. 86, 239-254 (1968).
7. Sakai, M., Austin, J., Witmer, F. & Trueb, L. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20, 160-176 (1970).
8. Acharya, J.N., Satishchandra, P. & Shankar, S.K. Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 36, 429-434 (1995).
9. Berkovic, S.F., Cochius, J., Andermann, E. & Andermann, F. Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 34 (Suppl 3): S19-S30 (1993).
10. Kobayashi, K., Iyoda, K., Ohtsuka, Y., Ohtahara, S. & Yamada, M. Longitudinal clinicoelectrophysiologic study of a case of Lafora disease proven by skin biopsy. Epilepsia 31, 194-201 (1990).
11. Minassian, B.A. Lafora's disease: towards a clinical, pathologic andmolecular synthesis. Pediatr. Neurol. 25, 21-29 (2001).
12. Shahwan, A., Farrell, M. & Delanty, N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 4, 239-248 (2005).
13. Van Heycop Ten Ham, M.W. Lafora disease, a form of progressive myoclonues epilepsy. Handb. Clin. Neurol. 15, 382-422 (1974).
14. Minassian, B.A. et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20, 171-174 (1998).
15. Minassian, B.A. et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 55, 341-346 (2000).
16. Serratosa, J.M. et al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum. Mol. Genet. 8, 345-352 (1999).
17. Wang, J., Stuckey, J.A., Wishart, M.J. & Dixon, J.E. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J. Biol. Chem. 277, 2377-2380 (2002).
18. Ganesh, S., Puri, R., Singh, S., Mittal, S. & Dubey, D. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet. 51, 1-8 (2006).
19. Chan, E.M. et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 35, 125-127 (2003).
20. Gentry, M.S., Worby, C.A. & Dixon, J.E. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl. Acad. Sci. USA 102, 8501-8506 (2005).
21. Ferrer, J.C. et al. Control of glycogen deposition. FEBS Lett. 546, 127-132 (2003).
22. Gomis, R.R., Cid, E., Garcia-Rocha, M., Ferrer, J.C. & Guinovart, J.J. Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase. J. Biol. Chem. 277, 23246-23252 (2002).
23. Skurat, A.V., Dietrich, A.D. & Roach, P.J. Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. Diabetes 49, 1096-1100 (2000).
24. Ferrer, J.C., Baque, S. & Guinovart, J.J. Muscle glycogen synthase translocates from the cell nucleus to the cystosol in response to glucose. FEBS Lett. 415, 249-252 (1997).
25. Cid, E., Cifuentes, D., Baque, S., Ferrer, J.C. & Guinovart, J.J. Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase. FEBS J. 272, 3197-3213 (2005).
26. Skurat, A.V., Wang, Y. & Roach, P.J. Rabbit skeletalmuscle glycogen synthase expressed in COS cells. Identification of regulatory phosphorylation sites. J. Biol. Chem. 269, 25534-25542 (1994).
27. MacAulay, K. et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur. J. Biochem. 270, 3829-3838 (2003).
28. Printen, J.A., Brady, M.J. & Saltiel, A.R. PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism. Science 275, 1475-1478 (1997).
29. Fong, N.M. et al. Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J. Biol. Chem. 275, 35034-35039 (2000).
30. Berman, H.K., O'Doherty, R.M., Anderson, P. & Newgard, C.B. Overexpression of protein targeting to glycogen (PTG) in rat hepatocytes causes profound activation of glycogen synthesis independent of normal hormone- and substrate-mediated regulatory mechanisms. J. Biol. Chem. 273, 26421-26425 (1998).
31. Fernandez-Sanchez, M.E. et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase 1 that enhances glycogen accumulation. Hum. Mol. Genet. 12, 3161-3171 (2003).
32. Allaman, I., Pellerin, L. & Magistretti, P.J. Protein targeting to glycogen mRNA expression is stimulated by noradrenaline in mouse cortical astrocytes. Glia 30, 382-391 (2000).
33. Schlamowitz, M. On the nature of rabbit liver glycogen. II. Iodine absorption spectrum. J. Biol. Chem. 190, 519-527 (1951).
34. Lee, D.H. & Goldberg, A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403 (1998).
35. Villar-Palasi, C. & Guinovart, J.J. The role of glucose-6-phosphate in the control of glycogen synthase. FASEB J. 11, 544-558 (1997).
36. Simo, S. et al. Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation. Cereb. Cortex 17, 294-303 (2007).
37. Seoane, J. et al. Glucose-6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J. Biol. Chem. 271, 23756-23760 (1996).
38. Becker, T.C. et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43 (Pt A): 161-189 (1994).
39. McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614-617 (1988).
40. Hojlund, K. et al. Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes 52, 1393-1402 (2003).
41. Baba, O. [Production of monoclonal antibody that recognizes glycogen and its application for immunohistochemistry.]. Kokubyo Gakkai Zasshi. 60, 264-287 (1993).
42. Chan, T.M. & Exton, J.H. A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal. Biochem. 71, 96-105 (1976).
43. Lang, G. & Michal, G. D-glucose-6-phosphate and D-Fructose-6-phosphate. in Methods of Enzymatic Analysis (ed. Bergmeyer, H. U.) 1238-1242 (Academic Press, New York, 1974).
44. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
45. Thomas, J.A., Schlender, K.K. & Larner, J. A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Anal. Biochem. 25, 486-499 (1968).
46. Guinovart, J.J. et al. Glycogen synthase: a new activity ratio assay expressing a high sensitivity to the phosphorylation state. FEBS Lett. 106, 284-288 (1979).